Literature DB >> 20177363

Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy.

Shane Lloyd1, James B Yu, Lynn D Wilson, Roy H Decker.   

Abstract

OBJECTIVES: The effect of adjuvant radiation therapy (RT) on survival in patients with adenoid cystic carcinoma (ACC) is much debated. Studies with large numbers of patients and long follow-up are lacking in the literature.
METHODS: We identified 2286 single-primary ACCs of the head and neck treated with surgery in the National Cancer Institute's surveillance, epidemiology, and end results database. The determinants of survival, including the effect of adjuvant RT, were analyzed with a Cox Proportional Hazards Model.
RESULTS: The overall 5-, 10-, 15-, 20-, and 25-year survival rates for patients receiving surgical resection were 77.3%, 59.6%, 44.9%, 35.0%, 25.5%, respectively. In the interval between 10 and 30 years after diagnosis, 111 patients died of ACC, and 137 died of all competing causes combined. Increasing stage caused a decrease in survival that was proportional over time. On multivariable analysis, distant metastasis, lymph node involvement, higher T classification, increasing age, and submandibular gland, or sinus/nasal cavity subsites were each independently associated with decreased overall and cause-specific survival. Adjuvant RT failed to improve overall or cause-specific survival.
CONCLUSIONS: Cause-specific survival continues to decline up to 30 years after diagnosis in ACC of the head and neck. In the interval between 10 and 30 years after diagnosis, patients are nearly as likely to die of ACC as from all competing causes combined. Certain clinicopathological factors are associated with decreased survival. There is no evidence of increased survival in patients receiving adjuvant RT.

Entities:  

Mesh:

Year:  2011        PMID: 20177363     DOI: 10.1097/COC.0b013e3181d26d45

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  54 in total

1.  A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry.

Authors:  Nan Li; Li Xu; Hui Zhao; Adel K El-Naggar; Erich M Sturgis
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

2.  Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.

Authors:  Monali Swain; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Roshan Patil; Vedang Murthy; Tejpal Gupta; Naveen Mummudi; Kumar Prabhash; Amit Joshi; Vijay Maruti Patil; Vanita Naronha; Jai Prakash Agarwal
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-09       Impact factor: 2.503

Review 3.  Genetic alterations in salivary gland cancers.

Authors:  Linda X Yin; Patrick K Ha
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

4.  Dedifferentiated adenoid cystic carcinoma of the nasopharynx: a rare entity of head and neck cancer.

Authors:  Ian S Boon; Adrian T Warfield; Shahzada K Ahmed; Cheng S Boon; Andrew Hartley
Journal:  BMJ Case Rep       Date:  2016-07-08

5.  Clinicopathological review and survival characteristics of adenoid cystic carcinoma.

Authors:  Fariba Binesh; Ali Akhavan; Omid Masumi; Abbas Mirvakili; Nasim Behniafard
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-05

6.  Cellular subtype may predict survival outcomes in salivary adenoid cystic carcinoma patients-a single-institution experience.

Authors:  Ehab Y Hanna; Ahmed S A Abdelmeguid; Dianna Roberts; Achim H Bell; Randal S Weber; Diana Bell
Journal:  Virchows Arch       Date:  2017-10-23       Impact factor: 4.064

Review 7.  Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck.

Authors:  T Subramaniam; P Lennon; J P O'Neill
Journal:  Ir J Med Sci       Date:  2015-04-17       Impact factor: 1.568

8.  Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.

Authors:  Julie Massé; Caroline Truntzer; Romain Boidot; Emmanuel Khalifa; Gaëlle Pérot; Valérie Velasco; Laétitia Mayeur; Claire Billerey-Larmonier; Larry Blanchard; Hélène Charitansky; Isabelle Soubeyran; Richard Iggo; Laurent Arnould; Gaëtan MacGrogan
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

9.  A Rare Case of Adenoid Cystic Carcinoma Isolated in the Mastoid.

Authors:  Jie Zhang; Hu Tingting; Yi Jin; Wu Xianmin; He Li; Chen Xiaoyun
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

10.  Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming.

Authors:  Henry F Frierson; Christopher A Moskaluk
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.